FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1569344663> ?p ?o ?g. }

• W1569344663 endingPage "07" @default.
• W1569344663 startingPage "S2" @default.
• W1569344663 abstract "Abstract Background: Anthracycline/taxane based regimen are standard of care for neoadjuvant therapy in breast cancer. A reverse sequence of taxanes followed by anthracyclines was suggested to achieve higher pCR rates (H.Earl, Lancet Oncol 2014). Dual HER2 blockade was shown to be superior to trastuzumab alone increasing the pCR rate by 20%. Nab-paclitaxel (nP) is a solvent-free formulation of paclitaxel (P) encapsulated in albumin which might further improve the pCR rate in breast cancer patients receiving neoadjuvant treatment and cause lower toxicity. Methods: In the GeparSepto study (NCT01583426) patients were randomized to either nP (125 mg/m2) q1w or P (80mg/m2) q1w for 12 weeks followed by 4 cycles of conventionally dosed EC (E, epirubicin 90mg/m2; C, cyclophosphamide 600 mg/m2) q3w. The primary objective is to compare the pathological complete response rate (pCR, ypT0 ypN0). Further objectives are to compare the pCR rate in predefined subgroups, pCR by other definitions, clinical response rate, rate of breast conserving surgery and toxicity and compliance. Patients with untreated, histologically confirmed uni- or bilateral, cT2- cT4d carcinoma, and no clinically relevant cardiovascular and other co-morbidities were included. HER2+ patients received trastuzumab (loading dose 8mg/kg; 6 mg/kg) plus pertuzumab (loading dose 840 mg; 420 mg) q3w concomitantly. HER2, estrogen receptor, progesterone receptor, Ki67 and SPARC status were centrally assessed prior to randomization for stratification. To increase the pCR rate from 33% with P to 41% with nP, corresponding to an odds ratio of 1.41 with an alpha of 0.05 and a power of 80%, 1200 patients would be needed. A window-of opportunity study was integrated to investigate response to anti-HER2 treatment without chemotherapy, HER2+ patients were randomized to receive 6 weeks of either trastuzumab, pertuzumab or the combination with biomaterial collection at the start and the end of the window. Results: A total of 1204/1229 (window study n=71) recruited patients (7/2012 - 12/2013) from 69 German centers were evaluable, 606 receiving nP. Baseline characteristics are well balanced; median age was 49/50 years (P/nP), 33/33% of the patients presented with HER2+ tumors, 23/23% triple negative breast cancer TNBC (ER and PR &lt;1 %), 87/85% ductal invasive, 56/52% G3 tumors; Ki67&gt;20% 69/69%; SPARC positive 15.7/16%. 265 patients reported SAEs (119 P/146 nP) and 4 died on study (1 P: cardiac decompensation; 3 nP: accident at home, multiorgan failure, sepsis during EC). The pCR rate (ypT0 ypN0) is 29% with P and 38% with nP, OR 1.5; p&lt;0.01. Conclusions: GeparSepto showed that the pCR rate is significantly higher with nab-paclitaxel compared to solvent-based paclitaxel given weekly before anthracycline based chemotherapy. Subgroupanalyses and 2ndary endpoints will be presented at the meeting. The trial was financially supported by Roche and Celgene. The window-substudy was funded within the EU-FP7 project RESPONSIFY No 278659. Citation Format: Michael Untch, Christian Jackisch, Andreas Schneeweiß, Bettina Conrad, Bahriye Aktas, Carsten Denkert, Holger Eidtmann, Hermann Wiebringhaus, Sherko Kümmel, Jörn Hilfrich, Mathias Warm, Stefan Paepke, Marianne Just, Claus Hanusch, John Hackmann, Jens-Uwe Blohmer, Michael Clemens, Serban Dan Costa, Bernd Gerber, Valentina Nekljudova, Sibylle Loibl, Gunter von Minckwitz. A randomized phase III trial comparing neoadjuvant chemotherapy with weekly nanoparticle-based paclitaxel with solvent-based paclitaxel followed by anthracyline/cyclophosphamide for patients with early breast cancer (GeparSepto); GBG 69 [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9-13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2015;75(9 Suppl):Abstract nr S2-07." @default.
• W1569344663 created "2016-06-24" @default.
• W1569344663 creator A5002071285 @default.
• W1569344663 creator A5003405177 @default.
• W1569344663 creator A5004942036 @default.
• W1569344663 creator A5010482169 @default.
• W1569344663 creator A5011410319 @default.
• W1569344663 creator A5014934109 @default.
• W1569344663 creator A5016987068 @default.
• W1569344663 creator A5024469109 @default.
• W1569344663 creator A5024741688 @default.
• W1569344663 creator A5026613913 @default.
• W1569344663 creator A5033698551 @default.
• W1569344663 creator A5040331693 @default.
• W1569344663 creator A5049792647 @default.
• W1569344663 creator A5056688392 @default.
• W1569344663 creator A5056873538 @default.
• W1569344663 creator A5057181684 @default.
• W1569344663 creator A5069170386 @default.
• W1569344663 creator A5071658752 @default.
• W1569344663 creator A5074391693 @default.
• W1569344663 creator A5087224341 @default.
• W1569344663 creator A5087559224 @default.
• W1569344663 creator A5089392438 @default.
• W1569344663 date "2015-05-01" @default.
• W1569344663 modified "2023-10-04" @default.
• W1569344663 title "Abstract S2-07: A randomized phase III trial comparing neoadjuvant chemotherapy with weekly nanoparticle-based paclitaxel with solvent-based paclitaxel followed by anthracyline/cyclophosphamide for patients with early breast cancer (GeparSepto); GBG 69" @default.
• W1569344663 doi "https://doi.org/10.1158/1538-7445.sabcs14-s2-07" @default.
• W1569344663 hasPublicationYear "2015" @default.
• W1569344663 type Work @default.
• W1569344663 sameAs 1569344663 @default.
• W1569344663 citedByCount "12" @default.
• W1569344663 countsByYear W15693446632015 @default.
• W1569344663 countsByYear W15693446632016 @default.
• W1569344663 countsByYear W15693446632018 @default.
• W1569344663 crossrefType "journal-article" @default.
• W1569344663 hasAuthorship W1569344663A5002071285 @default.
• W1569344663 hasAuthorship W1569344663A5003405177 @default.
• W1569344663 hasAuthorship W1569344663A5004942036 @default.
• W1569344663 hasAuthorship W1569344663A5010482169 @default.
• W1569344663 hasAuthorship W1569344663A5011410319 @default.
• W1569344663 hasAuthorship W1569344663A5014934109 @default.
• W1569344663 hasAuthorship W1569344663A5016987068 @default.
• W1569344663 hasAuthorship W1569344663A5024469109 @default.
• W1569344663 hasAuthorship W1569344663A5024741688 @default.
• W1569344663 hasAuthorship W1569344663A5026613913 @default.
• W1569344663 hasAuthorship W1569344663A5033698551 @default.
• W1569344663 hasAuthorship W1569344663A5040331693 @default.
• W1569344663 hasAuthorship W1569344663A5049792647 @default.
• W1569344663 hasAuthorship W1569344663A5056688392 @default.
• W1569344663 hasAuthorship W1569344663A5056873538 @default.
• W1569344663 hasAuthorship W1569344663A5057181684 @default.
• W1569344663 hasAuthorship W1569344663A5069170386 @default.
• W1569344663 hasAuthorship W1569344663A5071658752 @default.
• W1569344663 hasAuthorship W1569344663A5074391693 @default.
• W1569344663 hasAuthorship W1569344663A5087224341 @default.
• W1569344663 hasAuthorship W1569344663A5087559224 @default.
• W1569344663 hasAuthorship W1569344663A5089392438 @default.
• W1569344663 hasConcept C121608353 @default.
• W1569344663 hasConcept C126322002 @default.
• W1569344663 hasConcept C126894567 @default.
• W1569344663 hasConcept C143998085 @default.
• W1569344663 hasConcept C2776694085 @default.
• W1569344663 hasConcept C2776755627 @default.
• W1569344663 hasConcept C2776802502 @default.
• W1569344663 hasConcept C2777292972 @default.
• W1569344663 hasConcept C2777511904 @default.
• W1569344663 hasConcept C2778292576 @default.
• W1569344663 hasConcept C2779786085 @default.
• W1569344663 hasConcept C2780835546 @default.
• W1569344663 hasConcept C2781164504 @default.
• W1569344663 hasConcept C2781190966 @default.
• W1569344663 hasConcept C2781413609 @default.
• W1569344663 hasConcept C530470458 @default.
• W1569344663 hasConcept C71924100 @default.
• W1569344663 hasConcept C90924648 @default.
• W1569344663 hasConceptScore W1569344663C121608353 @default.
• W1569344663 hasConceptScore W1569344663C126322002 @default.
• W1569344663 hasConceptScore W1569344663C126894567 @default.
• W1569344663 hasConceptScore W1569344663C143998085 @default.
• W1569344663 hasConceptScore W1569344663C2776694085 @default.
• W1569344663 hasConceptScore W1569344663C2776755627 @default.
• W1569344663 hasConceptScore W1569344663C2776802502 @default.
• W1569344663 hasConceptScore W1569344663C2777292972 @default.
• W1569344663 hasConceptScore W1569344663C2777511904 @default.
• W1569344663 hasConceptScore W1569344663C2778292576 @default.
• W1569344663 hasConceptScore W1569344663C2779786085 @default.
• W1569344663 hasConceptScore W1569344663C2780835546 @default.
• W1569344663 hasConceptScore W1569344663C2781164504 @default.
• W1569344663 hasConceptScore W1569344663C2781190966 @default.
• W1569344663 hasConceptScore W1569344663C2781413609 @default.
• W1569344663 hasConceptScore W1569344663C530470458 @default.
• W1569344663 hasConceptScore W1569344663C71924100 @default.
• W1569344663 hasConceptScore W1569344663C90924648 @default.
• W1569344663 hasIssue "9_Supplement" @default.
• W1569344663 hasLocation W15693446631 @default.
• W1569344663 hasOpenAccess W1569344663 @default.
• W1569344663 hasPrimaryLocation W15693446631 @default.

• next